Buprenorphine/naloxone - one formulation that doesn't fit all: a case report

Abstract Background Sublingual buprenorphine, approved for treatment of opioid use disorder since 2002, is most commonly available in co-formulation with naloxone. Naloxone is an opioid antagonist minimally absorbed when sublingual (SL) buprenorphine/naloxone is taken as prescribed; it is thought to...

Olles dieđut

Furkejuvvon:
Bibliográfalaš dieđut
Váldodahkkit: Hannan M. Braun (Dahkki), Jessica L. Taylor (Dahkki), Sarah Axelrath (Dahkki)
Materiálatiipa: Girji
Almmustuhtton: BMC, 2024-07-01T00:00:00Z.
Fáttát:
Liŋkkat:Connect to this object online.
Fáddágilkorat: Lasit fáddágilkoriid
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!

Interneahtta

Connect to this object online.

3rd Floor Main Library

oažžasuvvan: 3rd Floor Main Library
Hildobáiki: A1234.567
Njađus 1 Oažžumis